Sabestomig

N/A

Report date: 2024/04/17 17:46:56

Base Information

Drug NameSabestomig
Drug Alias NameAZD-7789
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitorsProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsHepatitis A virus cellular receptor 2Programmed cell death protein 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursNeoplasm Metastasis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstraZeneca Ag
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursNeoplasm Metastasis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A